Actuate Therapeutics Inc. has announced positive results from the phase 1 portion of its phase 1/2 clinical study (Actuate-1902; NCT 04239092) evaluating elraglusib, a GSK-3β inhibitor, in pediatric patients with relapsed or refractory cancers. Data from the trial showed two complete metabolic responses in patients with metastatic Ewing sarcoma and one complete response in a patient with metastatic neuroblastoma. Clinical responses and disease control were observed in 15 of 40 patients overall, including 10 of 19 patients treated with elraglusib in combination with cyclophosphamide and topotecan. Based on these results, Actuate plans to advance clinical development of elraglusib for Ewing sarcoma and potentially neuroblastoma, with additional clinical trials expected to begin in 2026. The company has been granted Rare Pediatric Disease Designations from the FDA for both indications. The results have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9620381) on January 06, 2026, and is solely responsible for the information contained therein.